ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer

NCT06543836 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

68

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: Sintilimab
DRUG: Fruquintinib or Regorafenib
DRUG: Fruquintinib

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences